Pegvisomant
Also known as: Somavert
Pegvisomant is a genetically engineered growth hormone receptor antagonist that blocks the action of growth hormone at the cellular level. This synthetic peptide analog contains multiple point mutations that enable it to bind to GH receptors without activating them, effectively reducing IGF-1 production.
Pegvisomant is a 22,129 Da research peptide. Pegvisomant is a genetically engineered growth hormone receptor antagonist that blocks the action of growth hormone at the cellular level. This synthetic peptide analog contains multiple point mutations that enable it to bind to GH receptors without activating them, effectively reducing IGF-1 production.
Also called: Somavert
22,129
Molecular Weight
Daltons
2
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
10-40
Typical Dose
mg
Overview
Pegvisomant represents a unique approach to managing growth hormone excess by functioning as a competitive antagonist at the GH receptor level. The molecule is created through site-directed mutagenesis of human growth hormone, incorporating nine amino acid substitutions that prevent receptor activation while maintaining high binding affinity. The addition of polyethylene glycol chains increases its half-life and reduces immunogenicity. Unlike somatostatin analogs that suppress GH release, pegvisomant blocks GH action directly at target tissues. This mechanism makes it particularly effective at normalizing IGF-1 levels even when GH secretion remains elevated. Research applications focus on understanding growth hormone signaling pathways, investigating metabolic effects of GH blockade, and studying tissue-specific responses to growth hormone antagonism. The compound provides researchers with a tool to selectively inhibit GH action without affecting other pituitary hormones.
Key Takeaways: Pegvisomant
- Strongest evidence supports Pegvisomant for igf-1 normalization and metabolic research applications
- Research doses typically range from 10 to 40 mg via subcutaneous
- 2 benefits with strong evidence, 3 moderate, 1 preliminary
- Half-life: 72-96 hours
- 4 cited research studies in this guide
Mechanism of Action
Pegvisomant functions as a competitive antagonist at the growth hormone receptor by binding with high affinity but failing to induce the conformational changes necessary for signal transduction. The molecule contains mutations at positions 120 (Gly→Arg) and 179 (Asp→Ala) that prevent receptor dimerization and activation. Additional mutations enhance binding affinity while the pegylation reduces proteolytic degradation and extends circulation time. This blockade prevents GH-stimulated IGF-1 production in the liver and other tissues, effectively creating a state of functional GH deficiency despite normal or elevated GH levels.
Research Benefits
Pegvisomant at a Glance
Pegvisomant functions as a competitive antagonist at the growth hormone receptor by binding with high affinity but failing to induce the conformational changes necessary for signal transduction.
IGF-1 Normalization
Strong EvidenceEffectively reduces elevated IGF-1 levels by blocking growth hormone receptor signaling, with studies showing normalization rates of 63-97% depending on dose and duration.
Metabolic Research Applications
Strong EvidenceProvides insight into GH-independent metabolic pathways by selectively blocking growth hormone action while preserving other hormonal functions.
Tissue-Specific GH Studies
Moderate EvidenceEnables investigation of growth hormone's differential effects across various tissues by providing targeted receptor antagonism.
Insulin Sensitivity Research
Moderate EvidenceDemonstrates improved glucose tolerance and insulin sensitivity in research models through growth hormone blockade.
Cardiovascular Parameter Studies
Moderate EvidenceResearch shows potential improvements in left ventricular mass and blood pressure parameters through GH receptor antagonism.
Body Composition Research
PreliminaryInvestigations reveal changes in lean body mass and fat distribution patterns following growth hormone receptor blockade.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| IGF-1 suppression studies | 10–40 mg | subcutaneous |
| Metabolic research protocols | 15–30 mg | subcutaneous |
Frequency
Daily administration
Timing
Consistent timing preferred, typically evening
Cycle Length
4-12 weeks for research protocols
Research Notes
- 1Dose escalation typically needed to achieve target IGF-1 levels
- 2Individual response varies significantly
- 3Baseline IGF-1 measurement essential before initiation
- 4Research purposes only - not for human consumption
Reconstitution Guide
Standard Reconstitution
Vial Size
10 mg
Bacteriostatic Water
1 mL
Concentration
100 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Pegvisomant vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 28 days after reconstitution.
Storage Temperature
2-8°C refrigerated
Shelf Life
28 days after reconstitution
Important Notes
- •Pre-filled syringes available for research use
- •Powder form requires reconstitution with provided diluent
- •Do not shake vigorously during preparation
- •Single-use vials - discard after use
Pegvisomant Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Pegvisomant Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions and lipodystrophy
- !Elevated liver enzymes (transaminases)
- !Fatigue and decreased energy levels
- !Joint pain and arthralgia
- !Peripheral edema
- !Headache and dizziness
- !Nausea and gastrointestinal upset
- !Increased sweating
- !Potential antibody formation
- !Hypoglycemia risk in diabetic subjects
Potential Interactions
- ⚡Insulin and antidiabetic medications - may require dose adjustment
- ⚡Opioid analgesics - altered analgesic requirements possible
- ⚡Cortisol replacement therapy - monitoring needed
- ⚡Growth hormone - direct antagonistic interaction
- ⚡Somatostatin analogs - potential additive effects on IGF-1
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pegvisomant in acromegaly: A multicenter study of efficacy and safety
Demonstrated effective IGF-1 normalization in 89% of subjects with dose-dependent response over 12 weeks of treatment.
Long-term safety and efficacy of pegvisomant treatment
Extended follow-up study showing sustained IGF-1 control with acceptable safety profile over extended treatment periods.
Effects of pegvisomant on glucose homeostasis and insulin sensitivity
Research demonstrated improved insulin sensitivity and glucose tolerance following growth hormone receptor antagonism.
Cardiovascular effects of growth hormone receptor blockade
Investigation of cardiac structure and function changes during pegvisomant treatment in research protocols.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Pegvisomant blocks growth hormone action at the receptor level rather than suppressing GH release from the pituitary. This provides more direct control over GH effects and can normalize IGF-1 even when GH levels remain elevated.
IGF-1 levels begin declining within 24-48 hours, with maximum suppression typically achieved within 2-4 weeks of consistent dosing at effective levels.
Research protocols may combine pegvisomant with somatostatin analogs or other compounds, but careful monitoring is required due to potential additive effects and interaction risks.
Regular IGF-1 measurements, liver function tests, and glucose monitoring are essential. Some protocols also track lipid profiles and cardiovascular parameters.
Dosing is typically individualized based on baseline IGF-1 levels and target suppression goals, with titration based on response rather than fixed protocols.
Unopened vials require refrigeration at 2-8°C. Reconstituted solutions remain stable for up to 28 days under proper refrigerated storage conditions.
Liver disease, pregnancy, and certain metabolic conditions may preclude use. Comprehensive health screening is essential before research protocol initiation.
IGF-1 levels typically return to baseline within 2-4 weeks of discontinuation, with the rate depending on individual clearance and underlying GH status.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.